Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?
about
A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes.A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.Progress in the development of immunotherapy for the treatment of patients with cancer.Absent Toll-like receptor-9 expression predicts poor prognosis in renal cell carcinomaCancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsDabrafenib in metastatic melanoma: a monocentric 'real life' experience.PRAME expression in hairy cell leukemia.PRAME expression and clinical outcome of breast cancerUpdate on vaccine development for renal cell cancer.Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Tumor lysate-loaded biodegradable microparticles as cancer vaccines.Limited expression of cancer-testis antigens in renal cell carcinoma patients.Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.
P2860
Q24814644-D088DAE2-26D2-4562-97B0-FB58C9A88C2FQ33597549-C6E8E25D-8055-4F80-9D77-A5F4285B2626Q33745923-9F56310B-AB55-46C0-A588-5E7E508844E5Q34029148-96BF3772-9102-4E7B-9026-C76DE6C2160FQ34570245-A107E3F9-0730-4CB6-9ED3-41463FF1AACFQ35241051-C4F265FD-ABEC-40ED-A5F0-72BD90B762D1Q36623761-F9F7F0D0-2496-44BB-B179-AB05DAEEEAA6Q36652790-49C3B3F6-FAF7-41C9-9B38-4F1298F115D5Q36748859-106E452B-5E71-4A2D-A132-7C1D0924D3EDQ36858038-D769C7CC-FFCB-46D7-A5A3-E3AC66CADC5FQ36989720-8769CF55-E8DF-410C-9D73-C0ECCE5BCBF2Q37066106-5E6B05BB-A2AE-470C-A31D-796542A1D288Q37074226-E2E5B3AD-8620-4F03-89C1-B0DBF3933B0AQ37670779-15D38F33-C8B5-410A-9DB9-9F16C91671C9Q38292778-C3983941-6ACB-43CF-A127-FE724465A8C2Q38305306-7C5903E9-2B10-47C5-B279-32BD10CB644BQ38588894-D9B0EE6A-4601-4B9F-870E-50DFC1A637E5
P2860
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?
description
1998 nî lūn-bûn
@nan
1998 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@ast
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@en
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@nl
type
label
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@ast
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@en
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@nl
prefLabel
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@ast
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@en
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@nl
P2093
P1433
P1476
Heterogeneous expression of th ...... T-cell-based immunotherapies?
@en
P2093
Engelsberg A
P304
P407
P577
1998-09-01T00:00:00Z